Integrin activation controls metastasis in human breast cancer
- Brunhilde Felding-Habermann*,†,
- Timothy E. O'Toole‡,
- Jeffrey W. Smith§,
- Emilia Fransvea*,¶,
- Zaverio M. Ruggeri*,
- Mark H. Ginsberg‡,
- Paul E. Hughes‡,
- Nisar Pampori‡,
- Sanford J. Shattil‡,
- Alan Saven‖, and
- Barbara M. Mueller**
- *Departments of Molecular and Experimental Medicine, ‡Vascular Biology, and **Immunology, The Scripps Research Institute; §The Burnham Institute; and ‖The Scripps Clinic, La Jolla, CA 92037
-
Communicated by Ernest Beutler, The Scripps Research Institute, La Jolla, CA (received for review July 13, 2000)
Abstract
Metastasis is the primary cause of death in human breast cancer. Metastasis to bone, lungs, liver, and brain involves dissemination of breast cancer cells via the bloodstream and requires adhesion within the vasculature. Blood cell adhesion within the vasculature depends on integrins, a family of transmembrane adhesion receptors, and is regulated by integrin activation. Here we show that integrin αvβ3 supports breast cancer cell attachment under blood flow conditions in an activation-dependent manner. Integrin αvβ3 was found in two distinct functional states in human breast cancer cells. The activated, but not the nonactivated, state supported tumor cell arrest during blood flow through interaction with platelets. Importantly, activated αvβ3 was expressed by freshly isolated metastatic human breast cancer cells and variants of the MDA-MB 435 human breast cancer cell line, derived from mammary fat pad tumors or distant metastases in severe combined immunodeficient mice. Expression of constitutively activated mutant αvβ3D723R, but not αvβ3WT, in MDA-MB 435 cells strongly promoted metastasis in the mouse model. Thus breast cancer cells can exhibit a platelet-interactive and metastatic phenotype that is controlled by the activation of integrin αvβ3. Consequently, alterations within tumors that lead to the aberrant control of integrin activation are expected to adversely affect the course of human breast cancer.
Footnotes
-
↵ † To whom reprint requests should be addressed at: The Scripps Research Institute, Molecular and Experimental Medicine, MEM 175, 10550 N. Torrey Pines Road, La Jolla, CA 92037. E-mail: brunie{at}scripps.edu.
-
↵ ¶ Present address: Clinica Medica II, Piazza G. Cesare 11, 70122 Bari, Italy.
- Copyright © 2001, The National Academy of Sciences





